This site is intended for US healthcare professionals only.

    Graphic showing the overall response rate

    ORR*:

    29%

    Response Rates

    SD2: 8.2%

    (95% CI: 22-38)

    N=134

    For your adult patients with relapsed or refractory diffuse large B-cell lymphoma
    (RR DLBCL) who have received at least 2 lines of systemic therapy1
    with XPOVIO® (selinexor), the first and only FDA-approved, oral single agent that targets the cell nucleus to block XPO1
    Data above demonstrated in a clinical trial of 134 adult patients with RR DLBCL, NOS, who had received 2 to 5 systemic regimens and were not eligible for autologous HSCT.
    *Responses were assessed by an Independent Radiologic Review Committee (IRC) using Lugano 2014 criteria.
    Includes CR + PR.
    CI=confidence interval, CR=complete response, HSCT=hematopoietic stem cell transplantation,
    NOS=not otherwise specified, ORR=overall response rate, PR=partial response, SD=stable disease.

    References: 1. XPOVIO (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; June 2020. 2. Data on file. Karyopharm Therapeutics Inc.

    INDICATIONS

    • XPOVIO® (selinexor) in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
    • XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

    IMPORTANT SAFETY INFORMATION

    Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in patients with DLBCL.

    Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.